These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 22413476)

  • 21. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.
    Niesvizky R; Naib T; Christos PJ; Jayabalan D; Furst JR; Jalbrzikowski J; Zafar F; Mark T; Lent R; Pearse RN; Ely S; Leonard JP; Mazumdar M; Chen-Kiang S; Coleman M
    Br J Haematol; 2007 Sep; 138(5):640-3. PubMed ID: 17686058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversible pulmonary toxicity due to lenalidomide.
    Coates S; Barker A; Spurgeon S
    J Oncol Pharm Pract; 2012 Jun; 18(2):284-6. PubMed ID: 21742815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lenalidomide-induced acute interstitial nephritis.
    Lipson EJ; Huff CA; Holanda DG; McDevitt MA; Fine DM
    Oncologist; 2010; 15(9):961-4. PubMed ID: 20709889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interstitial pneumonitis associated with the immunomodulatory drugs thalidomide and lenalidomide.
    Iino M
    Int J Hematol; 2012 Feb; 95(2):223-4. PubMed ID: 22198829
    [No Abstract]   [Full Text] [Related]  

  • 25. Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients.
    Reneau JC; Asante D; van Houten H; Sangaralingham LR; Buadi FK; Lerman A; Herrmann J
    Am J Hematol; 2017 Feb; 92(2):E15-E17. PubMed ID: 27813147
    [No Abstract]   [Full Text] [Related]  

  • 26. Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma.
    Niesvizky R; Martínez-Baños D; Jalbrzikowski J; Christos P; Furst J; De Sancho M; Mark T; Pearse R; Mazumdar M; Zafar F; Pekle K; Leonard J; Jayabalan D; Coleman M
    Leuk Lymphoma; 2007 Dec; 48(12):2330-7. PubMed ID: 18067007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study.
    Luo J; Gagne JJ; Landon J; Avorn J; Kesselheim AS
    Eur J Cancer; 2017 Jan; 70():22-33. PubMed ID: 27866096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma.
    Cejalvo MJ; de la Rubia J
    Future Oncol; 2015; 11(11):1643-58. PubMed ID: 25857329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma.
    Dasanu CA; Alexandrescu DT
    Eur J Haematol; 2009 Mar; 82(3):231-4. PubMed ID: 19018868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The use of lenalidomide in the treatment of multiple myeloma].
    Holánek M; Hájek R
    Klin Onkol; 2010; 23(2):67-72. PubMed ID: 20465083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.
    Palumbo A; Freeman J; Weiss L; Fenaux P
    Expert Opin Drug Saf; 2012 Jan; 11(1):107-20. PubMed ID: 22066855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lenalidomide and its role in the management of multiple myeloma.
    Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cerebral venous thrombosis in an individual with multiple myeloma treated with lenalidomide.
    Eudo C; Petit A; Mondon K; Rippault H; Dardaine V; Constans T; Hommet C; Cottier JP
    J Am Geriatr Soc; 2011 Dec; 59(12):2371-2. PubMed ID: 22188080
    [No Abstract]   [Full Text] [Related]  

  • 34. Thalidomide-associated hyperglycemia and diabetes: case report and review of literature.
    Pathak RD; Jayaraj K; Blonde L
    Diabetes Care; 2003 Apr; 26(4):1322-3. PubMed ID: 12663627
    [No Abstract]   [Full Text] [Related]  

  • 35. Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment.
    Zhou DB; Yu L; Du X; Jin J; Cai Z; Chen F; Ke X; Li X; Wu D; Meng F; Ai H; Zhang J; DeMarco D; Chen N; Mei J; Wang J; Hou J
    Int J Hematol; 2015 Jun; 101(6):569-77. PubMed ID: 25753225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of the adverse effects of lenalidomide in multiple myeloma.
    González Rodríguez AP
    Adv Ther; 2011 Mar; 28 Suppl 1():1-10. PubMed ID: 21431626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.
    Stadtmauer EA; Lonial S; Vesole DH; Abonour R; Alsina M; Badros A; Comenzo R; Durie B; Giralt S; Hussein M; Jakubowiak A; Mehta J; Niesvizky R; Orlowski R; Siegel D; Singhal S; Vescio R; Wang M; Zangari M; Munshi NC
    Clin Adv Hematol Oncol; 2007 Oct; 5(10 Suppl 15):7-19, quiz 21-2. PubMed ID: 18000495
    [No Abstract]   [Full Text] [Related]  

  • 38. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
    Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
    Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stevens-Johnson/toxic epidermal necrolysis overlap syndrome following lenalidomide treatment for multiple myeloma relapse after allogeneic transplantation.
    Wäsch R; Jakob T; Technau K; Finke J; Engelhardt M
    Ann Hematol; 2012 Feb; 91(2):287-9. PubMed ID: 21494796
    [No Abstract]   [Full Text] [Related]  

  • 40. Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?
    Mateos MV; García-Sanz R; Colado E; Olazábal J; San-Miguel J
    Br J Haematol; 2008 Feb; 140(3):324-6. PubMed ID: 18067473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.